# Treatment of Primary CNS Lymphoma ( FTD )

> **NCT05274139** · PHASE2 · COMPLETED · sponsor: **Mingzhi Zhang** · enrollment: 20 (actual)

## Conditions studied

- Primary CNS Lymphoma (PCNSL)

## Interventions

- **DRUG:** HD-MTX-Ara-C regimen
- **DRUG:** FTD regimen

## Key facts

- **NCT ID:** NCT05274139
- **Lead sponsor:** Mingzhi Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-02
- **Primary completion:** 2019-03-02
- **Final completion:** 2019-03-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05274139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05274139, "Treatment of Primary CNS Lymphoma ( FTD )". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05274139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*